venBio Global Strategic — Full Portfolio
19 tracked investments · listed companies and verified rows first
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)Mark Bradley(Chief Development Officer)Kolbot By(SVP, Head of Technical Operations)Jack Danilkowicz(Chief Commercial Officer)Jörn Drappa(Chief Medical Officer)David M Goldstein(Chief Scientific Officer)
Board seatRichard Gaster· per SEC Form D · $259M raise · filed Mar 2024
Co-investorsForesite CapitalNextech InvestOrbiMedSamsara BioCapitalSR One Capital ManagementvenBio Partners+1 more
San Diego, US
Board seatYvonne Yamanaka· per SEC Form D · $120M raise · filed Apr 2021
Co-investors5AM VenturesRA Capital
Aeovian Pharmaceuticals is a clinical-stage biopharmaceutical company developing selective small molecule inhibitors to treat rare genetic and age-related diseases caused by dysregulated cellular metabolism.
BiotechBerkeley, US
Allison J. Hulme(CEO & President)John Kincaid(Chief Scientific Officer)Davis Ryman(Executive Officer)Micah Zajic(Executive Officer)Ian Massey(Executive Officer)Stelios Tzannis(Executive Officer, Director)
Board seatRichard Gaster· per SEC Form D · $50.4M raise · filed May 2024
Co-investorsCoastCapCTI Life Sciences Fund L.P.FJ LabsSofinnova VenturesvenBio Partners
Arpeggio Bio develops pharmaceutical drugs that target transcription factors using artificial intelligence and RNA-sequencing technology, with lead programs in development for melanoma treatment and rare disease applications.
BiotechHealthtechBoulder, US
Joey Azofeifa(Founder)inJoseph G. Azofeifa(Executive Officer, Director)Laura Norris(Executive Officer, Director)Timothy Read(Executive Officer, Director)Eric Martin(Executive Officer)
BoardAmit Mehta(Director)
Board seatAaron Royston· per SEC Form D · $35.3M raise · filed Nov 2025
Co-investorsFifty YearsFundersClubTau VenturesvenBio PartnersY CombinatorBoxOne Ventures+1 more
Attralus develops pan-amyloid removal (PAR) therapeutics — biologics and imaging agents designed to bind and remove toxic amyloid — to treat patients with systemic amyloidosis across all disease types and stages.
BiotechHealthtechSouth San Francisco, US
Jonathan Wall(Executive Officer)Spencer Guthrie(Executive Officer)Mark Timney(Executive Officer, Director)Benson Fong(Executive Officer)Rahul Kakkar(Director)Greg Bell(Executive Officer)
Board seatCorey GoodmanRichard Gaster· per SEC Form D · $56M raise · filed Feb 2024
Co-investorsAlpha Wave GlobalBioBritvenBio Partners
BiotechCambridge, US
Praveen Tipirneni(Executive Officer, Director)
BoardMichelle Doig(Director)inMichael Gladstone(Director)inXiaodi Su(Director)
Board seatAaron Royston· per SEC Form D · $37.5M raise · filed Jan 2026
Co-investorsAtlas VentureBain Capital Life SciencesJanus Henderson InvestorsLAVOmega FundsvenBio Partners+1 more
Entact is a drug discovery company developing treatments for patients.
BiotechDeep TechWatertown, US
Victoria Richon(Executive Officer, Director, Promoter)Ruben Tommasi(Chief Scientific Officer)Michael Gutch(Chief Operating Officer)Alon Lazarus(Director)
BoardAndrew Sinclair(Director)Anna French(Director)
Board seatRichard Gaster· per SEC Form D · $10M raise · filed Jun 2026
Co-investorsvenBio Partners
Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapies for serious eye diseases such as wet age-related macular degeneration and diabetic macular edema using the TransCon technology platform.
BiotechDigital HealthMedical DevicesRedwood City, US
Emmett Cunningham(Executive Officer, Director)Mark Bachleda(Executive Officer, Director)inRobert Vitti(Executive Officer)Oliver Stauch(Executive Officer)inOliver Boris Stauch(Executive Officer)Conrad Wang(Director)
Board seatYvonne Yamanaka· per SEC Form D · $89.8M raise · filed Oct 2025
Co-investorsFrazier Life SciencesHealthQuest CapitalvenBio Partners
FogPharma develops ultra-tunable Helicon peptide therapeutics designed to reach historically undruggable targets, aiming to treat cancer and other serious diseases.
BiotechBoston, US
Gregory L Verdine(Executive Officer, Director)Mathai Mammen(CEO, President and Chairman)
Board seatCorey S. Goodman· per SEC Form D · $178M raise · filed Dec 2022
Co-investorsCatalio Capital Management, LPHorizons VenturesGV (Google Ventures)
West Hills, US
Board seatYvonne Yamanaka· per SEC Form D · $141.8M raise · filed Apr 2024
Co-investorsDecheng CapitalNovartis Venture FundRMGP Biopharma Investment Fund
HealthtechSeattle, US
John D. Hoekman(Executive Officer, Director)
BoardMichael Hite(Director)Stewart Parker(Director)
Board seatAaron Royston· per SEC Form D · $1.9M raise · filed Apr 2021
Co-investors5AM VenturesB Capital GroupvenBio PartnersWestlake Village BioPartners
Insamo develops an automated platform for drug discovery that designs, synthesizes, and tests cyclic peptides at scale using machine learning and proprietary experimental data.
AI & Machine LearningBiotechDeep TechChippendale, AU
TIMOTHY CRAVEN(Executive Officer, Director)TOBY PASSIOURA(Executive Officer, Director)Tim Craven(CEO)Toby Passioura(CSO)Glen McIntyre(COO)GLEN MCINTYRE(Executive Officer, Director)
Board seatCorey Goodman· per SEC Form D · $2.3M raise · filed Dec 2023
Co-investorsCivilization Ventures Management, LlcMRL Ventures FundPlayground GlobalvenBio PartnersAxial VC
Developing transformative therapies to advance treatment of gastrointestinal disorders with significant unmet medical need.
Woburn, US
Board seatAaron Royston· per SEC Form D · filed Jul 2021
Co-investorsSamsara BioCapitalWestlake Village BioPartners
Boston, US
Board seatCorey Goodman· per SEC Form D · $4M raise · filed Jul 2023
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)Ben Hickey(President)Abhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
Board seatAaron Royston· per SEC Form D · $167.9M raise · filed Sep 2022
Co-investorsSamsara BioCapitalScion Life SciencesSofinnova VenturesTCG CrossovervenBio PartnersVersant Ventures+1 more
HealthtechIrvine, US
Kenny Chang(Executive Officer)W. Ronald Redmond(Director)Vijay Dhaka(Executive Officer)Philong Pham(Executive Officer, Director)Hongsheng Tong(Executive Officer, Director)
Board seatAaron Royston· per SEC Form D · $112M raise · filed Sep 2021
Co-investorsBlackRockEndeavour VisionMVM Life Science PartnersRTW Investments L.P.Soleus CapitalVivo Capital
Tallac Therapeutics is a biopharmaceutical company developing oligonucleotide-based antibody drug conjugates (ADCs) to treat cancer, including its Toll-like Receptor Agonist Antibody Conjugates (TRAAC) that deliver a TLR9 agonist to activate immune responses within the tumor microenvironment.
BiotechHealthtechBurlingame, US
Board seatCorey Goodman· per SEC Form D · $61.6M raise · filed Jul 2021
Co-investorsLightstone VenturesMRL Ventures FundvenBio Partners
San Diego, US
Mark S. Forman(Executive Officer)Matthew Moore(Executive Officer)John Nuss(Executive Officer)Jigar Choksey(Director)Martin Auster(Executive Officer)Christopher W. Krueger(Executive Officer)
Board seatAaron RoystonRichard Gaster· per SEC Form D · $51M raise · filed Sep 2021
Co-investorsNew Science VenturesThird Point VenturesvenBio PartnersSilverArc Private
Axonis Therapeutics is a drug discovery company developing first-in-class therapies for currently incurable neurological disorders.
BiotechDeep TechHealthtechMedical DevicesBoston, US
Shane Hegarty(Executive Officer)Shane V. Hegarty(Chief Scientific Officer & Co-Founder)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Chief Executive Officer, President & Co-Founder)Jeff Imbaro(Chief Operating Officer)Tiasha Shafiq(Chief of Staff)
Co-investorsCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture PartnersIaso VenturesLumira VenturesPathway Bioventures+6 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.